NVS•November 18, 2026 at 4:45 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Novartis Wins FDA Approval for Cosentyx in Polymyalgia Rheumatica

Read source article

What happened

Novartis received FDA approval for Cosentyx (secukinumab) in adults with polymyalgia rheumatica (PMR), backed by Phase III data showing sustained remission and steroid-sparing benefits compared with placebo. This marks a new indication for an already blockbuster immunology brand, but the revenue impact is likely incremental relative to Novartis's priority growth drivers like Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio. The approval does not address the company's central challenge: Entresto generic erosion caused H1 2026 group sales to fall 2% in constant currency and operating margin to drop to 32.6%. While the steroid-sparing profile may differentiate Cosentyx in PMR, the drug is already subject to Medicare price negotiation starting 2028, limiting pricing upside. Consequently, this news is a modest positive but unlikely to shift the valuation debate, which hinges on late-2026 pipeline catalysts and evidence that launch brands can offset the patent cliff.

Implication

This approval adds a new indication to a mature blockbuster, likely providing incremental revenue in immunology but unlikely to move the needle on near-term group growth. The steroid-sparing benefit could support uptake in an underserved PMR population, but competition and pricing pressure (Cosentyx is under IRA negotiation) may limit upside. For existing holders, it reinforces the breadth of the franchise but does not alter the WAIT rating or the need for evidence of enterprise-level offset. For new investors, it slightly improves the bull case but does not eliminate the margin-of-safety concerns at current levels. Monitor how quickly the label expands and whether it adds meaningful revenue in 2027.

Thesis delta

The approval strengthens Cosentyx's competitive position in immunology but does not change the core thesis that Novartis must demonstrate that its growth brands can offset Entresto erosion while maintaining margins. It adds a modest positive catalyst but does not resolve the premium valuation concern or the need for pipeline validation. The WAIT rating and entry levels remain unchanged; the approval should be treated as a minor positive offset within the existing bear-to-base scenario.

Confidence

Medium-High